Drug Trial Radar · NCT06715540
Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Mar 29, 2024
Primary completion
Feb 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses to healthy male subjects aged from 18 to 45 years old. The study consists of the first stage (dose escalation) and the second stage (dose expansion).
Conditions
- Healthy
Interventions
BCD-261, dose 1Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, dose 2Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, dose 3Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, dose 4Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, dose 5Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, dose 6Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, pre-specified therapeautic dose XDrug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
BCD-261, pre-specified therapeautic dose XDrug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
BCD-261, pre-specified therapeautic dose YDrug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with adverse reactionsTime frame: 127 days
- Proportion of subjects with serious adverse reactionsTime frame: 127 days
- Proportion of subjects with CTCAE 5.0 grade 3 or higher adverse reactionsTime frame: 127 days
- Proportion of subjects who prematurely withdrew from the study due to adverse reactionsTime frame: 127 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
"Meditsinskiy teсhnologiy Maly"
Saint Petersburg, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.